Dr. John F. Ledoux, M.D.
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,064
Licensed in Alabama since 2002, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of South Alabama College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
AL license MD.24847 (first issued 2002; active) -
Cardiovascular Disease Physician
AL license 24847 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mobile Infirmary Medical Center Mobile, AL
- USA Health HCA Providence Hospital, LLC Mobile, AL
- USA Health University Hospital Mobile, AL
- Springhill Medical Center Mobile, AL
- George Regional Health System Lucedale, MS
Medical groups
- Cardiology Associates of Mobile Inc (54 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,064
- Services billed
- 9,777
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,455 | 54 |
| Injection, regadenoson, 0.1 mg | 756 | 188 |
| Established patient office or other outpatient visit, 30-39 minutes | 627 | 444 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 366 | 183 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 323 | 295 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 287 | 155 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 236 | 26 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 207 | 204 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 179 | 179 |
| Ultrasound of both sides of head and neck blood flow | 163 | 162 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Mobile, AL | 2,025 |
| Atorvastatin Calcium Other prescribers in Mobile, AL | 1,015 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Mobile, AL | 987 |
| Ezetimibe Other prescribers in Mobile, AL | 948 |
| Metoprolol Succinate Other prescribers in Mobile, AL | 609 |
| Carvedilol Other prescribers in Mobile, AL | 557 |
| Eliquis (apixaban) Other prescribers in Mobile, AL | 428 |
| Furosemide Other prescribers in Mobile, AL | 372 |
| Losartan Potassium Other prescribers in Mobile, AL | 308 |
| Lisinopril Other prescribers in Mobile, AL | 294 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 20 payments worth $353 in total to this clinician.
| Merck Sharp & Dohme LLC | $82.21 |
|---|---|
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $60.41 |
| Novartis Pharmaceuticals Corporation | $46.28 |
| Abbott Laboratories | $43.28 |
| Penumbra, Inc. | $39.87 |
| Actelion Pharmaceuticals US, Inc. | $27.77 |
| Esperion Therapeutics, Inc. | $20.94 |
| Argon Medical Devices, Inc. | $17.73 |
| Food and Beverage | $353 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $732,417 in research payments for these studies, mostly to the institutions running them.
- HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.